LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 573

Search options

  1. Article: Juveniler systemischer Lupus erythematodes. Juvenile systemic lupus erythematosus

    Horneff, G.

    Pädiatrische Praxis

    2023  Volume 100, Issue 1, Page(s) 110

    Language German
    Document type Article
    ZDB-ID 123435-3
    ISSN 0030-9346
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Neue Therapieoptionen bei der juvenilen idiopathischen. Therapeutic Options for Juvenile Idiopathic Arthritis

    Horneff, G.

    Pädiatrische Praxis

    2021  Volume 95, Issue 3, Page(s) 491

    Language German
    Document type Article
    ZDB-ID 123435-3
    ISSN 0030-9346
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Innovationen in der Behandlung der juvenilen idiopathischen Arthritis

    Horneff, Gerd

    Pädiatrie up2date

    2022  Volume 17, Issue 04, Page(s) 337–353

    Keywords juvenilen idiopathischen Arthritis ; NSAR ; TNF-Inhibitoren ; Interleukin-Inhibitoren ; targeted synthetic small molecules
    Language German
    Publishing date 2022-12-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2256194-8
    ISSN 1862-9393 ; 1611-6445
    ISSN (online) 1862-9393
    ISSN 1611-6445
    DOI 10.1055/a-1210-4138
    Database Thieme publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6448: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: CME. Genetische autoinflammatorische Syndrome. CME. Genetic autoinflammatory syndrome

    Horneff, G.

    Pädiatrische Praxis

    2019  Volume 92, Issue 3, Page(s) 493

    Language German
    Document type Article
    ZDB-ID 123435-3
    ISSN 0030-9346
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Protokolle in der Kinderrheumatologie (PROKIND): Treat-to-Target bei polyartikulärer juveniler idiopathischer Arthritis.

    Horneff, G / Minden, K / Foell, D / Klotsche, J / Tenbrock, K

    Zeitschrift fur Rheumatologie

    2023  Volume 83, Issue 1, Page(s) 15–27

    Abstract: Background: The aims of the PROKIND protocols are improvement and harmonization of the diagnostics, monitoring, treatment decision and prognosis.: Material and methods: This article reports the results of a prospective treat-to-target observational ... ...

    Title translation Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis.
    Abstract Background: The aims of the PROKIND protocols are improvement and harmonization of the diagnostics, monitoring, treatment decision and prognosis.
    Material and methods: This article reports the results of a prospective treat-to-target observational study of patients with polyarticular juvenile idiopathic arthritis (JIA) during the first year of treatment. Disease activity was assessed with the 10-joint juvenile arthritis disease activity score (JADAS-10), functional limitation with the childhood health assessment questionnaire disability index (CHAQ-DI) and with information on overall well-being, on pain, on fatigue and on global estimation of disease activity.
    Results: Overall, 129 patients with polyarticular JIA (rheumatoid factor, RF, positive (+) polyarthritis n = 22, RF negative (-) polyarthritis n = 133 from 23 pediatric rheumatology institutions in Germany and Austria were recruited. Patients with initial treatment with methotrexate formed cohort 1, patients with additional repeated intravenous corticosteroid pulse therapy formed cohort 2 and patients with concomitant intra-articular corticosteroid administration in at least 5 joints formed cohort 3. The mean JADAS10 showed a decrease in disease activity from 16.4 ± 6.1 to 2.8 ± 3.6 and the decrease in the CHAQ-DI from 1.0 ± 0.8 to 0.3 ± 0.5 showed the improvement in functional capacity. Similarly, improvements in quality of life, pain and fatigue were demonstrable. A JADAS inactive disease was achieved by 18.1% at month 3, 47.7% at month 6 and 66.7% at month 12. In cohort 1 a JADAS remission was achieved by 72.4%, by 50% in cohort 2 and by 69.2% in cohort 3. An escalation to treatment with biologics was necessary in 38% of patients in cohort 1, 60% in cohort 2 and 46% in cohort 3.
    Conclusion: Using a treat-to-target approach a dramatic improvement in disease activity, functional capacity and quality of life in polyarticular JIA could be achieved. Even after 12 months an inactive disease was achieved in the majority of cases.
    MeSH term(s) Child ; Humans ; Arthritis, Juvenile/diagnosis ; Arthritis, Juvenile/drug therapy ; Antirheumatic Agents/therapeutic use ; Quality of Life ; Prospective Studies ; Rheumatology ; Treatment Outcome ; Adrenal Cortex Hormones/therapeutic use ; Pain ; Observational Studies as Topic
    Chemical Substances Antirheumatic Agents ; Adrenal Cortex Hormones
    Language German
    Publishing date 2023-12-29
    Publishing country Germany
    Document type English Abstract ; Journal Article
    ZDB-ID 124985-x
    ISSN 1435-1250 ; 0340-1855 ; 0301-6382
    ISSN (online) 1435-1250
    ISSN 0340-1855 ; 0301-6382
    DOI 10.1007/s00393-023-01452-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.128: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Entzündliche Gelenkerkrankungen

    Horneff, G.

    Monatsschrift Kinderheilkunde

    2018  Volume 166, Issue 7, Page(s) 572

    Language German
    Document type Article
    ZDB-ID 137102-2
    ISSN 0026-9298
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Um IV Zs.45: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Autoinflammatorische Syndrome im Kindesalter.

    Horneff, G

    Zeitschrift fur Rheumatologie

    2015  Volume 74, Issue 6, Page(s) 511–24; quiz 525

    Abstract: Systemic autoinflammatory diseases are a group of hereditary and non-hereditary diseases of the innate immune system, characterized by inflammation with no apparent cause, recurrence at irregular intervals and manifestation on the skin, mucous membranes, ...

    Title translation Autoinflammatory syndromes in childhood.
    Abstract Systemic autoinflammatory diseases are a group of hereditary and non-hereditary diseases of the innate immune system, characterized by inflammation with no apparent cause, recurrence at irregular intervals and manifestation on the skin, mucous membranes, joints, bone, gastrointestinal tract, blood vessels and the central nervous system (CNS). Amyloidosis and other possibly severe long-term complications are important. Advances in genetics and molecular biology have improved understanding of the pathogenesis of these diseases, including familial Mediterranean fever, mevalonate kinase deficiency syndrome, tumor necrosis factor receptor-associated periodic syndrome, cryopyrin-associated periodic syndrome and improved others. The vast majority of these diseases are based on activation of the interleukin-1 (IL-1) pathway, so that inhibition of IL-1 provides a therapeutic option. Other syndromes are characterized by a granulomatous inflammation. Newer autoinflammatory diseases, such as chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) and stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) are, however, driven by interferons.
    MeSH term(s) Genetic Predisposition to Disease/genetics ; Hereditary Autoinflammatory Diseases/genetics ; Hereditary Autoinflammatory Diseases/immunology ; Humans ; Immunity, Innate/immunology ; Interleukin-1/genetics ; Interleukin-1/immunology ; Models, Genetic ; Models, Immunological
    Chemical Substances Interleukin-1
    Language German
    Publishing date 2015-08
    Publishing country Germany
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 124985-x
    ISSN 1435-1250 ; 0340-1855 ; 0301-6382
    ISSN (online) 1435-1250
    ISSN 0340-1855 ; 0301-6382
    DOI 10.1007/s00393-015-1572-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.128: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Treatment of non-systemic juvenile idiopathic arthritis.

    Shenoi, Susan / Horneff, Gerd / Aggarwal, Amita / Ravelli, Angelo

    Nature reviews. Rheumatology

    2024  Volume 20, Issue 3, Page(s) 170–181

    Abstract: In the past two decades, the treatment of juvenile idiopathic arthritis (JIA) has evolved markedly, owing to the availability of a growing number of novel, potent and relatively safe therapeutic agents and the shift of management strategies towards early ...

    Abstract In the past two decades, the treatment of juvenile idiopathic arthritis (JIA) has evolved markedly, owing to the availability of a growing number of novel, potent and relatively safe therapeutic agents and the shift of management strategies towards early achievement of disease remission. However, JIA encompasses a heterogeneous group of diseases that require distinct treatment approaches. Furthermore, some old drugs, such as methotrexate, sulfasalazine and intraarticular glucocorticoids, still maintain an important therapeutic role. In the past 5 years, information on the efficacy and safety of drug therapies for JIA has been further enriched through the accomplishment of several randomized controlled trials of newer biologic and synthetic targeted DMARDs. In addition, a more rational therapeutic approach has been fostered by the promulgation of therapeutic recommendations and guidelines. A multinational collaborative effort has led to the development of the recommendations for the treat-to-target strategy in JIA. There is currently increasing interest in establishing the optimal time and modality for discontinuation of treatment in children with JIA who achieve sustained clinical remission. The aim of this Review is to summarize the current evidence and discuss the therapeutic approaches to the management of non-systemic phenotypes of JIA, including oligoarthritis, polyarthritis, enthesitis-related arthritis and psoriatic arthritis.
    MeSH term(s) Child ; Humans ; Arthritis, Juvenile/drug therapy ; Antirheumatic Agents/therapeutic use ; Methotrexate/therapeutic use ; Sulfasalazine/therapeutic use ; Arthritis, Psoriatic/drug therapy ; Treatment Outcome
    Chemical Substances Antirheumatic Agents ; Methotrexate (YL5FZ2Y5U1) ; Sulfasalazine (3XC8GUZ6CB)
    Language English
    Publishing date 2024-02-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/s41584-024-01079-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6338: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Biosimilars in der Kinderrheumatologie

    Horneff, Gerd

    Kinder- und Jugendmedizin

    2021  Volume 21, Issue 05, Page(s) 339–348

    Abstract: Mit der Einführung von Biosimilars für Etanercept und Adalimumab können diese zur primären Therapie der juvenilen idiopathischen Arthritis eingesetzt werden oder durch Umstellung/Switch vom Originator auf ein Biosimilar. Bislang liegen nur begrenzte ... ...

    Abstract Mit der Einführung von Biosimilars für Etanercept und Adalimumab können diese zur primären Therapie der juvenilen idiopathischen Arthritis eingesetzt werden oder durch Umstellung/Switch vom Originator auf ein Biosimilar. Bislang liegen nur begrenzte Daten über diesen Einsatz vor. Die Datenbank des nationalen BIKER-Registers wurde genutzt, um Erfahrungen aus der klinischen Praxis mit Etanercept- und Adalimumab-Biosimilars sowohl im head-to-head-Vergleich (n = 118) mit dem Originator als auch nach Switch (n = 117) zu beschreiben. Die Patientencharakteristika und Krankheitsaktivitätsparameter waren bei Therapiestart weitgehend vergleichbar. Kein Unterschied fand sich auch in der Effektivität. Ein Rückgang des JADAS10 zeigt eine vergleichbare Verbesserung in beiden Gruppen an. Auch Unterschiede in der Verträglichkeit ergaben sich nicht. Nach Switchung kann keine Verschlechterung der Krankheitsaktivität erkannt werden. Über besondere Hemmnisse bei der Anwendung von Biosimilars in der Kinderheumatologie kann nur spekuliert werden. Die bisherigen Erfahrungen sowohl bei der Ersteinstellung als auch beim Switching zu Biosimilars zeigen ermutigende Ergebnisse.
    Keywords Biosimilar ; Adalimumab ; Etanercept ; juvenile idiopathische Arthrtis ; Biosimilar ; adalimumab ; etanercept ; juvenile idiopathic arthritis
    Language German
    Publishing date 2021-10-01
    Publisher Georg Thieme Verlag KG,
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2223494-9
    ISSN 2567-577X ; 1617-0288
    ISSN (online) 2567-577X
    ISSN 1617-0288
    DOI 10.1055/a-1582-4635
    Database Thieme publisher's database

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Kinder- und Jugendmedizin

    Horneff, Gerd

    Kinder- und Jugendmedizin

    2021  Volume 21, Issue 05, Page(s) 311–312

    Language German
    Publishing date 2021-10-01
    Publisher Georg Thieme Verlag KG,
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2223494-9
    ISSN 2567-577X ; 1617-0288
    ISSN (online) 2567-577X
    ISSN 1617-0288
    DOI 10.1055/a-1591-6597
    Database Thieme publisher's database

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top